For: | Adinolfi LE, Guerrera B. All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality. World J Hepatol 2015; 7(22): 2363-2368 [PMID: 26464751 DOI: 10.4254/wjh.v7.i22.2363] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v7/i22/2363.htm |
Number | Citing Articles |
1 |
Martina Smolić, Tea Omanović, Ivana Božić, Ines Bilić-Ćurčić, Robert Smolić, Aleksandar Včev. Update on Hepatitis C. 2017; doi: 10.5772/intechopen.70794
|
2 |
Karen M. Clements, Parag S. Kunte, Melissa A. Clark, Deborah Gurewich, Bonnie C. Greenwood, Laura Sefton, Carter Pratt, Sharina D. Person, Miryea A. Wessolossky. Uptake of hepatitis C virus treatment in a multi‐state Medicaid population, 2013–2017. Health Services Research 2022; 57(6): 1312 doi: 10.1111/1475-6773.13994
|
3 |
Zhi-Wei Chen, Zhao Li, Qiao-He Wang, Xiao-Ling Wu, Hu Li, Hong Ren, Peng Hu. Large Disparity between Prevalence and Treatment Rates for Hepatitis C in Western China. Journal of Clinical and Translational Hepatology 2018; 6(X): 1 doi: 10.14218/JCTH.2018.00027
|
4 |
Luigi Elio Adinolfi, Riccardo Nevola, Luca Rinaldi, Ciro Romano, Mauro Giordano. Chronic Hepatitis C Virus Infection and Depression. Clinics in Liver Disease 2017; 21(3): 517 doi: 10.1016/j.cld.2017.03.007
|
5 |
Abdel‐Maaboud I. Mohamed, Azza H. Rageh, Fatma A. M. Abdel‐aal, Al‐Montaser Bellah H. Ali. Pencil Graphite Electrode Decorated with Xylenol Orange Flakes for Studying Possible Pharmacokinetic Interaction Between Vardenafil and Daclatasvir. Electroanalysis 2020; 32(3): 635 doi: 10.1002/elan.201900272
|
6 |
Juan Turnes, Raquel Domínguez-Hernández, Miguel Ángel Casado. Análisis coste-efectividad de dos estrategias de tratamiento para la hepatitis C crónica: antes y después del acceso a los agentes antivirales de acción directa en España. Gastroenterología y Hepatología 2017; 40(7): 433 doi: 10.1016/j.gastrohep.2017.05.004
|
7 |
Khashayar Hesamizadeh, Heidar Sharafi, Mohammad Saeid Rezaee-Zavareh, Bita Behnava, Seyed Moayed Alavian. Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals. Hepatitis Monthly 2016; 16(4) doi: 10.5812/hepatmon.37089
|
8 |
Juan Turnes, Raquel Domínguez-Hernández, Miguel Ángel Casado. Value and innovation of direct-acting antivirals: long-term health outcomes of the strategic plan for the management of hepatitis C in Spain. Revista Española de Enfermedades Digestivas 2017; doi: 10.17235/reed.2017.5063/2017
|
9 |
Maria Stepanova, Mehmet Sayiner, Leyla de Avila, Zahra Younoszai, Andrei Racila, Zobair M. Younossi. Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor. BMC Gastroenterology 2016; 16(1) doi: 10.1186/s12876-016-0551-z
|
10 |
Juan Turnes, Raquel Domínguez-Hernández, Miguel Ángel Casado. Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain. Gastroenterología y Hepatología (English Edition) 2017; 40(7): 433 doi: 10.1016/j.gastre.2017.07.008
|
11 |
Luigi Elio Adinolfi, Emanuele Durante Mangoni, Aldo Marrone, Rosa Zampino, Luca Rinaldi. Liver Diseases. 2020; : 181 doi: 10.1007/978-3-030-24432-3_17
|
12 |
Mohammad Ehsan Bayatpoor, Mohammad Hossein Khosravi, Heidar Sharafi, Mohammad Saeid Rezaee-Zavareh, Bita Behnava, Seyed Moayed Alavian. Sofosbuvir and Ribavirin with or Without Pegylated-Interferon in Hepatitis C Virus Genotype-2 or -3 Infections: A Systematic Review and Meta-Analysis. Archives of Clinical Infectious Diseases 2019; (In Press) doi: 10.5812/archcid.79465
|